Back to the future : the neurobiology of major depression" This issue of Psychological Medicine carries a number of papers on the neurobiology of major depression. Those acquainted with the field will recognize some familiar topics and while familiarity can be comforting, it can also raise a sense of unease ; as the millennium approaches should we still be enquiring about the role of decreased serotonin and increased cortisol in the pathophysiology of depressive disorders ?
cortisol\DHEA ratios were more likely to experience such life events. This leads the authors to speculate that one of the deleterious neurobiological effects of hypercortisolaemia could be to impair aspects of social cognition, thereby increasing the risk that such life events may be experienced.
There is, in fact, growing interest in the effect of cortisol on cognition, a topic addressed by Van Londen et al. (1998) in their study of depressed patients. There is a good body of evidence, from both human and animal studies, that excessive cortisol secretion can impair learning and memory (Sapolsky et al. 1986 ; Kirschbaum et al. 1996) . Conceivably then, excessive cortisol secretion could account for the cognitive deficits seen in depressed patients. While the literature is not without inconsistency the data of Van Londen et al. support those studies in which cortisol concentrations have been found to relate inversely to cognitive performance in depressed patients.
Against all this we need to keep the perspective that increased cortisol secretion is a normal and presumably adaptive response to stress. Are there positive ' trade-offs ', on cognitive performance and on mood, that we need to establish ? On the other hand, is it possible that subjects vulnerable to mood disturbance react in a different way to increased cortisol secretion ? Whether or not cortisol produces different neurobiological effects in those vulnerable to depression should be a tractable question.
TRYPTOPHAN DEPLETION, 5-HT AND MOOD
The paper by Neumeister et al. (1998) uses a technique called ' tryptophan depletion ' that has attracted growing interest since its effects on mood in healthy subjects were first described by Young et al. (1985) . The synthesis of 5-HT in the brain is dependent on the availability of its amino acid precursor, tryptophan (TRP), from plasma and manipulations that decrease plasma TRP concentrations can lower brain 5-HT synthesis (Fernstrom & Wurtman, 1971) .
In TRP depletion subjects are given a mixture of amino acids from which TRP has been omitted. Ingestion and absorption of this mixture stimulates protein synthesis, a process requiring TRP which is an essential amino acid. Because TRP has been omitted from the mixture the body uses its own tissue stores of TRP to manufacture protein (Gessa et al. 1974) . This causes plasma TRP concentrations to drop to about 20 % of normal values over the next 5 h. In addition, the neutral amino acids in the mixture compete with TRP for active transport across the blood-brain barrier, further lowering brain availability of TRP. Recent investigations using positron emission tomography (PET) with α-[11 C ]methyl--tryptophan have confirmed that TRP depletion lowers brain 5-HT synthesis in humans (Nishizawa et al. 1997) .
TRP depletion provides a simple dietary means of lowering brain 5-HT synthesis. It, therefore, allows direct investigation as to whether lowering brain 5-HT function does indeed play an important role in the pathophysiology of mood disorders. In its simplest form the 5-HT hypothesis of depression would predict that lowering brain 5-HT neurotransmission would be sufficient to cause clinical depression. This is clearly not the case. In subjects with no personal or family history of depression TRP depletion may cause a mild and inconsistent lowering of mood (Young et al. 1985 ; but clinical symptomatology is not seen.
The paper by Neumeister et al. adds to a growing body of data suggesting that in subjects with a history of depression (both seasonal and non-seasonal) who are fully recovered and off drug treatment, TRP depletion can cause an acute, temporary, symptomatic relapse (Moreno et al. 1996 ; Smith et al. 1997 b) . This suggests that low 5-HT may indeed play a role in the pathophysiology of depression but that it must interact with some other factor to produce clinical symptomatology.
It is conceivable that this factor could reside in the regulation of 5-HT synthesis. Perhaps those with a vulnerability to depression experience a greater impairment in 5-HT neurotransmission when TRP levels are lowered. PET imaging may provide a means of answering this question. It is, however, also quite possible that those vulnerable to depression have an abnormality in specific groups of neurones crucial to mood regulation and that neurotransmitters like 5-HT act to repair or protect these neurones perhaps by increasing intracellular levels of neurotropic factors (Duman et al. 1997) . From this viewpoint, lowering brain 5-HT neurotransmission could allow a critical underlying abnormality to be revealed.
Clearly, lowering brain 5-HT function by TRP depletion is a highly artificial manoeuvre. If diminished brain 5-HT function can precipitate depression in vulnerable subjects how might this occur in real life ? Interestingly, there may be a role for HPA axis activation because animal studies suggest that excessive cortisol secretion can lower brain 5-HT function by a number of mechanisms including stimulation of TRP metabolism and decreased expression of certain 5-HT receptors (Maes et al. 1990 ; Chaouloff, 1995) .
These effects of cortisol give rise to some intriguing possibilities by which psychosocial stress, HPA axis activation and lowered brain 5-HT function could interact to cause depression and cognitive impairment in vulnerable individuals (Deakin & Graeff, 1991) . There are also interesting questions about the impact of other risk factors such as genetic influences, early life experiences and temperament on these social and biological mechanisms. Our task is difficult because we have to ask questions that on the one hand permit the testing of clear and critical hypotheses and on the other do justice to the complexity of the biosocial mechanisms that we are studying. Unfortunately, biological psychiatry has not always been able to avoid the problem identified by Dr Johnson in one of his colleagues -' that fellow seems to me to possess but one idea, and that is a wrong one '.
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